Real-World Insight: Lenvatinib for RAI-Refractory DTC
Watch
Current Treatment Approaches for R/R DLBCL
Frontline Treatment Approaches in DLBCL
Lenvatinib Data for RAI-Refractory DTC
DLBCL: Cytogenetic Testing and Treatment Initiation
Systemic Therapy for RAI-Refractory DTC
Recommendations for Treating Patients With DTC
Approaching DLBCL: Risk Assessment and Prognosis
Case Impressions: A 73-Year-Old Woman With DTC
Case Overview: 77-Year-Old Woman With DLBCL
A 73-Year-Old Woman With Differentiated Thyroid Cancer
Andrew G. Gianoukakis, MD, of Harbor-UCLA Medical Center, describes the rationale for treating a patient with RAI-refractory differentiated thyroid cancer with systemic therapy.
A 77-Year-Old Woman with DLBCL
John M. Burke, MD, of Rocky Mountain Cancer Centers, explains the rationale behind treating an elderly woman with relapsed diffuse large B-cell lymphoma with tafasitamab and lenalidomide after R-CHOP chemotherapy.
ACCC President Highlights Oncology Community Response to COVID-19 Pandemic
Randall A. Oyer, MD, discusses the importance of the ACCC community during the unprecedented coronavirus disease 2019 pandemic.
L-MIND and RE-MIND Practical Implications
RE-MIND Comparison Data Review
Phase 2 L-MIND Trial Overview
Targeting CD19 in Diffuse Large B-Cell Lymphoma: Treatment Updates
A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.
Early Data Presented for Lenvatinib and Pembrolizumab in Thyroid Cancer
Christine Dierks, MD, discusses the early data from a study looking at the combination of lenvatinib and pembrolizumab in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma.
Novel Treatment Options in Diffuse Large B-Cell Lymphoma
L-MIND Trial Regimen Overview
Results of the L-MIND Clinical Trial
Initial Treatment of Diffuse Large B-Cell Lymphoma
Presentation of a Patient With Diffuse Large B-Cell Lymphoma
A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma
Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.
Tafasitamab Plus Lenalidomide Approval Generates Excitement for Second-Line DLBCL
Kami J. Maddocks, MD, discusses the role of tafasitamab and lenalidomide following the approval of this agent as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.
Novel Therapies in Advanced RCC
Lenvatinib and Everolimus for Advanced RCC
Second-Line Treatment Options for Advanced RCC
Advanced RCC Treatment Selection
Risk Stratification of Patients With Advanced RCC